Individualization of leflunomide dosing in rheumatoid arthritis patients

Personalized Medicine

Volumn 11, Issue 4, 2014, Pages 449-461

  Hopkins, Ashley M ^a   O'Doherty, Catherine E ^a   Foster, David J R ^a   Upton, Richard N ^a   Proudman, Susanna M ^b,c   Wiese, Michael D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

leflunomide; pharmacogenomics; rheumatoid arthritis; teriflunomide; therapeutic drug monitoring

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ALLERGY; ALOPECIA; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INFECTION; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84906247116     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.23     Document Type: Review

References (77)

1. Behrens F, Finkenwirth C, Pavelka K et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res. 65(3), 464-470 (2013).
2. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010).
3. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease - modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res. 59(6), 762-784 (2008).
4. Singh JA, Furst DE, Bharat A et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64(5), 625-639 (2012).
5. Proudman SM, Keen HI, Stamp LK et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin. Arthritis Rheum. 37(2), 99-111 (2007).
6. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 32(12), 1123-1134 (2009).
7. Cutolo M, Boloiu H, Perdriset G. Efficacy and safety of leflunomide in DMARD-naïve patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology 52(6), 1132-1140 (2013).
8. Bird P, Griffiths H, Tymms K et al. The SMILE study-safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J. Rheumatol. 40(3), 228-235 (2013).
9. Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J. Virol. 84(4), 2150-2156 (2010).
10. Hüttemann M, Shipkova M, Klett C et al. Total and free plasma concentrations of the active metabolite of leflunomide in relation to therapeutic outcome in kidney transplant recipients with BK-virus nephropathy. Transplant. Proc. 45, 1611-1613 (2013).
11. Teschner S, Gerke P, Geyer M et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant. Proc. 41, 2533-2538 (2009).
12. Breedveld F, Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Br. Med. J. 59(11), 841 (2000).
13. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 376(9746), 1094-1108 (2010).
14. Osiri M, Shea B, Welch V et al. Leflunomide for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 2002(3), CD002047 (2002).
15. Gaujoux-Viala C, Smolen JS, Landewé R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69(6), 1004-1009 (2010).
16. Ishaq M, Muhammad JS, Hameed K, Mirza AI. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. Modern Rheumatol. 21(4), 375-380 (2011).
17. Furst D, Keystone E, Fleischmann R et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 69(Suppl. 1), i2-i29 (2010).
18. Prakash A, Jarvis B. Leflunomide. A review of its use in active rheumatoid arthritis. Drugs 58(6), 1137-1164 (1999).
19. Emery P, Breedveld F, Lemmel E et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39(6), 655 (2000).
20. Chong A, Huang W, Liu W et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 68(1), 100 (1999).
21. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol. 50(6), 861-867 (1995).
22. Bruneau J, Yea C, Spinella-Jaegle S et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem. J. 336, 299-303 (1998).
23. Fox RI, Herrmann ML, Frangou CG et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93(3), 198-208 (1999).
24. Xu X, Blinder L, Shen J et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J. Immunol. 159(1), 167-174 (1997).
25. González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, Aragón-Bodi A, Sánchez BD, Sánchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann. Rheum. Dis. 68(10), 1644-1650 (2009).
26. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J. Immunol. 162(4), 2095-2102 (1999).
27. Chong A, Zeng H, Knight D et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am. J. Transplant. 6(1), 69-75 (2006).
28. Aletaha D, Stamm T, Kapral T et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Br. Med. J. 62(10), 944 (2003).
29. Van Riel PL, Smolen JS, Emery P et al. Leflunomide: a manageable safety profile. J. Rheumatol. 71, 21-24 (2004).
30. Sanofi-Aventis Australia: PRODUCT INFORMATION ARAVA® Leflunomide (2012). http://products.sanofi.com. au/aus-pi-arava.pdf
31. Curtis JR, Beukelman T, Onofrei A et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann. Rheum. Dis. 69(01), 43-47 (2010).
32. Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O et al. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand. J. Rheumatol. 42(6), 433-436 (2013).
33. Rozman B. Clin. Pharmacokinet. of leflunomide. Clin. Pharmacokinet. 41(6), 421-430 (2002).
34. Sanofi-Aventis: Clinical Pharmacology and Biopharmaceutics Review: Teriflunomide. FDA. Centre for Drug Evaluation and Research. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/2 02992Orig1s000ClinpharmR.pdf, 1-194 (2011).
35. Hoechst-Marion-Roussel: Clinical Pharmacology and Biopharmaceutics Review: Leflunomide (Arava). FDA. Centre for Drug Evaluation and Research. http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/20905-ARAVA-BIOPHARMR.PDF, 1-54 (1998).
36. Kalgutkar A, Nguyen H, Vaz A et al. In vitro metabolism studies on the isoxazole ring scission in the antiinflammatory agent leflunomide to its active-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos. 31(10), 1240 (2003).
37. Grabar B. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis. Drug Metab. Dispos. 37(10), 2061-2068 (2009).
38. Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'Doherty C. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin. Drug Metab. Toxicol. 9(8), 1025-1035 (2013).
39. Kis E, Nagy T, Jani M et al. Leflunomide and A771726, its metabolite are high affinity substrates of BCRPimplications for drug resistance. Ann. Rheum. Dis. 68(7), 1201 (2009).
40. Siva C, Eisen S, Shepherd R et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Care Res. 49(6), 745-751 (2003).
41. Bergner R, Peters L, Schmitt V, Löffler C. Leflunomide in dialysis patients with rheumatoid arthritis - a pharmacokinetic study. Clin. Rheumatol. 32(2), 267-270 (2013).
42. Russo PA, Wiese MD, Smith MD, Ahern MJ, Barbara JA, Shanahan EM. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. Ann. Pharmacother. 47(3), e15 (2013).
43. Chambers CD, Johnson DL, Robinson LK et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 62(5), 1494-1503 (2010).
44. AusPAR attachment 2, Extract from the Clinical Evaluation Report for Teriflunomide. Sponsor: Sanofi-Aventis Australia Pty Ltd to the Therapeutic Goods Administration (TGA). http://www.tga.gov.au/pdf/auspar/auspar- teriflunomide- 130521-cer.pdf, 1-181 (2012).
45. Van Roon EN, Jansen TLTA, Van De Laar Ma FJ et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(4), 569-574 (2005).
46. Schmidt A, Schwind B, Gillich M, Brune K, Hinz B. Simultaneous determination of leflunomide and its active metabolite, a77 1726, in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 17(4), 276-281 (2003).
47. Rakhila H, Rozek T, Hopkins A et al. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 55(2), 325-331 (2011).
48. Chan V, Charles B, Tett S. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br. J. Clin. Pharmacol. 60(3), 257 (2005).
49. Josephson MA, Gillen D, Javaid B et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81(5), 704-710 (2006).
50. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin. Chim. Acta 377(1-2), 1-13 (2007).
51. Shi J, Kovacs S, Wang Y, Ludden T, Bhargava V. Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J. Pharmacokinet. Pharmacodyn. 32(3), 419-439 (2005).
52. Aslibekyan S, Sha J, Redden DT et al. Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis. Ann. Rheum. Dis. 73(4), 785-786 (2013).
53. Grabar B, Rozman B, Tomši M, Šuput D, Logar D, Dolžan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 64(9), 871-876 (2008).
54. Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M. The effect of exon (19C> A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 10(2), 303-309 (2009).
55. Wiese M, Schnabl M, O'Doherty C et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res. Ther. 14(4), R163 (2012).
56. O'doherty C, Schnabl M, Spargo L et al. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics 13(12), 1427-1434 (2012).
57. International HapMap Project. (2014). http://hapmap.ncbi. nlm.nih.gov/
58. Grabar PB, Rozman B, Logar D, Praprotnik S, Dolžan V. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68(8), 1367-1368 (2009).
59. Dziedziejko V, Kurzawski M, Pawlik A. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 12(1), 41-47 (2011).
60. Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur. J. Clin. Pharmacol. 67(2), 129-134 (2011).
61. Chan EC, New L-S. In vitro metabolism of leflunomide by mouse and human liver microsomes. Drug Metab. Lett. 1(4), 299-305 (2007).
62. Chan EC, New LS, Yap CW, Goh LT. Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 23(3), 384-394 (2009).
63. Sokka T, Toloza S, Cutolo M et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res. Ther. 11(1), R7 (2009).
64. Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M. Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. Int. J. Clin. Exp. Med. 2(3), 221 (2009).
65. Cutolo M, Brizzolara R, Atzeni F, Capellino S, Straub RH, Puttini PCS. The immunomodulatory effects of estrogens. Ann. NY Acad. Sci. 1193(1), 36-42 (2010).
66. Kremer J, Genovese M, Cannon G et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann. Int. Med. 137(9), 726 (2002).
67. Kremer JM. Methotrexate and leflunomide: biochemicalbasis for combination therapy in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 29(1), 14-26 (1999).
68. Stamp L, Roberts R, Kennedy M, Barclay M, O'donnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis-are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother. 60(10), 678-687 (2006).
69. Dougados M, Emery P, Lemmel E, Zerbini C, Brin S, Van Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann. Rheum. Dis. 64(1), 44-51 (2005).
70. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65(13), 1825-1849 (2005).
71. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101(5), 1163 (1998).
72. Urushibara M, Takayanagi H, Koga T et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF - κB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 50(3), 794-804 (2004).
73. Yamasaki Y, Ieiri I, Kusuhara H et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin. Pharmacol. Ther. 84(1), 95-103 (2008).
74. Van Der Heijden J, De Jong M, Dijkmans B et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann. Rheum. Dis. 63(2), 131-137 (2004).
75. De Stefano R, Frati E, Nargi F et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexateanti-TNF-alpha. Clin. Rheumatol. 29(5), 517-524 (2010).
76. Strangfeld A, Hierse F, Kekow J et al. Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide. Ann. Rheum. Dis. 68(12), 1856-1862 (2009).
77. Kacevska M, Ivanov M, Ingelman-Sundberg M. Epigeneticdependent regulation of drug transport and metabolism: an update. Pharmacogenomics 13(12), 1373-1385 (2012). treatment in rheumatoid arthritis. Pharmacogenomics 13(12), 1427-1434 (2012).